BR112014016117A2 - herpevírus koi recombinante, método para a produção de partículas infecciosas de herpevírus koi recombinante, e , vacina para a prevenção e/ou tratamento terapêutico de uma doença em peixe causada por herpesvírus koi - Google Patents
herpevírus koi recombinante, método para a produção de partículas infecciosas de herpevírus koi recombinante, e , vacina para a prevenção e/ou tratamento terapêutico de uma doença em peixe causada por herpesvírus koiInfo
- Publication number
- BR112014016117A2 BR112014016117A2 BR112014016117-8A BR112014016117A BR112014016117A2 BR 112014016117 A2 BR112014016117 A2 BR 112014016117A2 BR 112014016117 A BR112014016117 A BR 112014016117A BR 112014016117 A2 BR112014016117 A2 BR 112014016117A2
- Authority
- BR
- Brazil
- Prior art keywords
- koi
- herpevirus
- recombinant
- vaccine
- prevention
- Prior art date
Links
- 241001051708 Cyprinid herpesvirus 3 Species 0.000 title 1
- 208000010824 fish disease Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002458 infectious effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16061—Methods of inactivation or attenuation
- C12N2710/16062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Farming Of Fish And Shellfish (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11196171 | 2011-12-30 | ||
| EP11196171.0 | 2011-12-30 | ||
| PCT/EP2012/076496 WO2013098214A1 (en) | 2011-12-30 | 2012-12-20 | A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014016117A2 true BR112014016117A2 (pt) | 2018-09-25 |
Family
ID=47429841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014016117-8A BR112014016117A2 (pt) | 2011-12-30 | 2012-12-20 | herpevírus koi recombinante, método para a produção de partículas infecciosas de herpevírus koi recombinante, e , vacina para a prevenção e/ou tratamento terapêutico de uma doença em peixe causada por herpesvírus koi |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140348875A1 (enExample) |
| EP (1) | EP2797627B1 (enExample) |
| JP (3) | JP5982009B2 (enExample) |
| CN (1) | CN104159609B (enExample) |
| BR (1) | BR112014016117A2 (enExample) |
| HU (1) | HUE053075T2 (enExample) |
| IL (1) | IL232902A0 (enExample) |
| IN (1) | IN2014CN04655A (enExample) |
| MD (1) | MD4481C1 (enExample) |
| MX (1) | MX361408B (enExample) |
| PH (1) | PH12014501388A1 (enExample) |
| PL (1) | PL2797627T3 (enExample) |
| RS (1) | RS61261B1 (enExample) |
| RU (1) | RU2662768C2 (enExample) |
| SG (1) | SG11201403066TA (enExample) |
| TW (1) | TWI484034B (enExample) |
| UA (2) | UA119786C2 (enExample) |
| WO (1) | WO2013098214A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014CN04655A (enExample) * | 2011-12-30 | 2015-09-18 | Université de Liège | |
| WO2017177071A1 (en) * | 2016-04-08 | 2017-10-12 | William Marsh Rice University | Improved galactose utilization |
| CN112279898B (zh) * | 2018-11-05 | 2022-06-21 | 共鳞实业(深圳)有限公司 | 预防或治疗鱼类感染CyHV-2的试剂及其应用 |
| EP3662929A1 (en) * | 2018-12-07 | 2020-06-10 | IDT Biologika GmbH | A recombinant koi herpesvirus (khv) and a diva vaccine for preventing and/or treating a disease caused by khv |
| CN110101854B (zh) * | 2019-05-14 | 2022-08-02 | 四川农业大学 | 一种鲤疱疹病毒ⅲ型疫苗及其制备方法 |
| CN110452926B (zh) * | 2019-08-07 | 2022-06-17 | 西北农林科技大学 | 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用 |
| CN110468111B (zh) * | 2019-08-07 | 2022-06-17 | 西北农林科技大学 | 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用 |
| CN113679832A (zh) * | 2021-05-24 | 2021-11-23 | 苏州大学 | 一种利用冷冻干燥制备杆状病毒载鲤疱疹病毒ii型dna疫苗的方法 |
| CN115960903B (zh) * | 2022-12-23 | 2023-09-08 | 中国水产科学研究院淡水渔业研究中心 | 一种抑制CyHV-2病毒增殖的反义RNA组、重组载体和纳米粒递送系统及应用 |
| CN120775802B (zh) * | 2025-06-13 | 2026-04-21 | 中国水产科学研究院珠江水产研究所 | 一种鲤疱疹病毒3型orf136基因失活株及其制备方法和应用 |
| CN120775801B (zh) * | 2025-06-13 | 2026-07-31 | 中国水产科学研究院珠江水产研究所 | 一种鲤疱疹病毒3型orf138基因失活株及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE115862T1 (de) | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | Tocole als impfstoffadjuvans. |
| DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| IL153775A0 (en) | 2003-01-01 | 2003-07-31 | Yissum Res Dev Co | Immunizing fish against viral infection |
| JP2007223913A (ja) * | 2006-02-21 | 2007-09-06 | Kyoritsu Seiyaku Kk | コイヘルペスウイルス病ワクチン |
| EP2011876B1 (en) * | 2006-04-13 | 2014-11-12 | National University Corporation Tokyo University of Marine Science and Technology | Dna vaccine for koi herpes virus (khv) disease |
| RU2010111725A (ru) * | 2007-08-28 | 2011-10-10 | Юниверсите Де Льеж (Be) | Рекомбинантный герпесвирус кои (khv) или герпесвирус 3 семейства карповых (cyhv-3) и вакцина для профилактики заболевания, вызванного khv/cyhv-3 у cyprinus carpio или cyprinus carpio koi |
| DE102007041332A1 (de) * | 2007-08-31 | 2009-03-05 | Siemens Ag | Transferchuck zur Übertragung, insbesondere von Wafern |
| IN2014CN04655A (enExample) * | 2011-12-30 | 2015-09-18 | Université de Liège |
-
2012
- 2012-12-20 IN IN4655CHN2014 patent/IN2014CN04655A/en unknown
- 2012-12-20 US US14/368,093 patent/US20140348875A1/en not_active Abandoned
- 2012-12-20 JP JP2014549442A patent/JP5982009B2/ja active Active
- 2012-12-20 UA UAA201702576A patent/UA119786C2/uk unknown
- 2012-12-20 RS RS20201561A patent/RS61261B1/sr unknown
- 2012-12-20 CN CN201280065496.XA patent/CN104159609B/zh active Active
- 2012-12-20 HU HUE12806062A patent/HUE053075T2/hu unknown
- 2012-12-20 BR BR112014016117-8A patent/BR112014016117A2/pt not_active Application Discontinuation
- 2012-12-20 EP EP12806062.1A patent/EP2797627B1/en active Active
- 2012-12-20 RU RU2014131474A patent/RU2662768C2/ru active
- 2012-12-20 UA UAA201408626A patent/UA114719C2/uk unknown
- 2012-12-20 SG SG11201403066TA patent/SG11201403066TA/en unknown
- 2012-12-20 WO PCT/EP2012/076496 patent/WO2013098214A1/en not_active Ceased
- 2012-12-20 MX MX2014008045A patent/MX361408B/es active IP Right Grant
- 2012-12-20 PL PL12806062T patent/PL2797627T3/pl unknown
- 2012-12-27 MD MDA20120127A patent/MD4481C1/ro not_active IP Right Cessation
- 2012-12-28 TW TW101150791A patent/TWI484034B/zh not_active IP Right Cessation
-
2014
- 2014-06-01 IL IL232902A patent/IL232902A0/en unknown
- 2014-06-18 PH PH12014501388A patent/PH12014501388A1/en unknown
-
2016
- 2016-04-14 JP JP2016081363A patent/JP2016195593A/ja active Pending
- 2016-05-25 US US15/164,010 patent/US9931396B2/en active Active
-
2018
- 2018-01-11 JP JP2018002936A patent/JP2018078903A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201403066TA (en) | 2014-10-30 |
| EP2797627B1 (en) | 2020-10-07 |
| CN104159609B (zh) | 2018-05-22 |
| EP2797627A1 (en) | 2014-11-05 |
| HUE053075T2 (hu) | 2021-06-28 |
| US9931396B2 (en) | 2018-04-03 |
| CN104159609A (zh) | 2014-11-19 |
| WO2013098214A1 (en) | 2013-07-04 |
| MD4481B1 (ro) | 2017-05-31 |
| MD20120127A2 (en) | 2013-07-31 |
| JP2018078903A (ja) | 2018-05-24 |
| TWI484034B (zh) | 2015-05-11 |
| MX2014008045A (es) | 2014-10-24 |
| MX361408B (es) | 2018-12-04 |
| IN2014CN04655A (enExample) | 2015-09-18 |
| TW201333201A (zh) | 2013-08-16 |
| US20140348875A1 (en) | 2014-11-27 |
| US20170028057A1 (en) | 2017-02-02 |
| PL2797627T3 (pl) | 2021-06-28 |
| JP5982009B2 (ja) | 2016-08-31 |
| PH12014501388A1 (en) | 2014-09-22 |
| JP2016195593A (ja) | 2016-11-24 |
| RS61261B1 (sr) | 2021-01-29 |
| UA119786C2 (uk) | 2019-08-12 |
| UA114719C2 (uk) | 2017-07-25 |
| RU2014131474A (ru) | 2016-02-20 |
| JP2015503914A (ja) | 2015-02-05 |
| RU2662768C2 (ru) | 2018-07-31 |
| MD4481C1 (ro) | 2017-12-31 |
| IL232902A0 (en) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1009034A2 (pt) | composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada a mesma | |
| HUE053409T2 (hu) | Ortopédiai szék a gerincbetegségek kezelésére és megelõzésére | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| GB2503066B8 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| BR112013029514A2 (pt) | composição imunogênica, vacina, e, método de tratar ou impedir uma doença | |
| IL232902A0 (en) | Recombinant koi distemper virus (khv) and a vaccine to prevent disease caused by khv | |
| SG10201604684WA (en) | Treatment of coagulation disease by administration of recombinant vwf | |
| PT2236149E (pt) | Composição medicinal para o tratamento de doenças infeciosas respiratórias | |
| GB2496800B (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition | |
| BR112013025340A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado com pi3k num indivíduo necessitado, método para tratar doença mediada por hdac e método para tratar tanto doenças mediadas por pi3k como por hdac | |
| IL260078B (en) | Therapy used to treat Gaucher disease | |
| PT2717887T (pt) | Métodos para tratamento ou prevenção da doença do enxerto contra hospedeiro | |
| GB201002243D0 (en) | Respiratory disease treatment | |
| BR112013006857A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica e método para o tratamento ou profilaxia de doenças virais | |
| GB201002224D0 (en) | Respiratory disease treatment | |
| IL234093A0 (en) | Preparations and dosages for oral administration and their uses for the treatment of Gaucher's disease | |
| EP2785335B8 (en) | Methods and pharmaceutical compositions for the treatment of darier disease | |
| GB201119358D0 (en) | Disubstituted triazine dimers for treatment and/or prevention of infectious diseases | |
| BR112015002053A2 (pt) | queijo, métodos de prevenir doenças ósseas, e, de produzir o queijo | |
| ZA201400442B (en) | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | |
| GB201113718D0 (en) | Treatment of Dupuytren's Disease | |
| TH1401003770A (th) | รีคอมบิแนนท์คอยเฮอร์ปีส์ไวรัส (khv) และวัคซีนสำหรับการป้องกันของโรคที่ได้รับการทำให้เกิดขึ้นโดย khv | |
| EP2789332A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING DIAMINODIPHENYLSULFONE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH BONE MASS REDUCTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: GESVAL S.A. (BE) |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |